Shi Jiazhuang Great Pharmaceutical Co.,Ltd

Primary objective: To observe the pharmacokinetic characteristics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg based on Asartan (C30H24N4O8); Manufacturer: Shijiazhuang Grey Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (Trade name: EDARBI; Specification: 80 mg based on Asartan (C30H24N4O8); Licensee: Takeda Pharma A/S) in healthy Chinese subjects after a single oral administration in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in healthy subjects in the fasting/fed state. Secondary objective: To observe the safety of the test preparation, Asartan Potassium Tablets and the reference preparation, Asartan Potassium Tablets (EDARBI) in healthy Chinese subjects.

A single-center, randomized, open, two-period, self-crossover, single-dose design was used to compare the differences in the extent and rate of absorption of arotinolol hydrochloride tablets (10 mg/tablet) produced by Shijiazhuang Grey Pharmaceutical Co., Ltd. and arotinolol hydrochloride tablets (10 mg/tablet, trade name: ALMARE®) produced by Sumitomo Dainippon Pharma Co., Ltd. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety and tolerability of arotinolol hydrochloride tablets produced by Shijiazhuang Grey Pharmaceutical Co., Ltd.

The main purpose of the study is to study the bioequivalence of the test preparation Probucol Tablets (Specification: 0.25g, licensed by Shijiazhuang Grey Pharmaceutical Co., Ltd.) and the reference preparation Probucol Tablets (Trade name: Lorelco®, Specification: 0.25g; licensed by Otsuka Pharmaceutical Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting/postprandial state. The secondary purpose of the study is to study the safety of the test preparation and the reference preparation in healthy adult subjects.